{"prompt": "['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', '12.7.2. Collection of Pregnancy Information', '85', '12.8. Appendix 8: Country Specific Requirements', '87', '12.9.', 'Appendix 9: protocol changes', '88', '8']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', '1.', 'PROTOCOL SYNOPSIS FOR STUDY 201749', 'Rationale', 'The primary purpose of this study is to demonstrate improvements in lung function in', 'subjects treated with Umeclidinium/Vilanterol (UMEC/VI) compared with Umeclidinium', '(UMEC) for 24 weeks. A further important aspect of the study is to evaluate the effect of', 'UMC/VI, UMEC, and salmeterol with respect to health-related quality of life (HRQoL),', 'measured through patient reported outcomes (PROs) questionnaires, and lung function.', 'Additional assessments to further evaluate other measures of chronic obstructive', 'pulmonary disease (COPD) efficacy and symptoms control will be performed.', 'Objective(s)/Endpoint(s)', 'Objectives', 'Enpoints', 'Primary', 'To compare the effect of UMEC/VI', 'Change from baseline in trough Forced', '(62.5/25 mcg once daily) with UMEC', 'Expiratory Volume in One Second', '(62.5 mcg once daily) on lung function', '(FEV1) at week 24', 'Secondary', 'To compare UMEC/VI (62.5/25 mcg', 'Change from baseline in self', 'once daily), UMEC (62.5 mcg once', 'administered computerised (SAC)', 'daily) with salmeterol (50 mcg twice', 'transient dyspnea index (TDI)', 'daily) on patient reported outcomes', '(PROs)', 'Percentage of TDI responders', 'according to SAC TDI score. A', 'responder is defined as a >1 unit', 'improvement in SAC TDI score', 'Assessment of respiratory daily', 'symptoms over 24 weeks using', 'Evaluating Respiratory Symptoms-', 'COPD (E-RS) and its subscales', '(breathlessness, cough and sputum and', 'chest symptoms)', 'Percentage of E-RS responders', 'according to E-RS score (defined as', 'reduction in E-RS score of >2 or >3.35', 'units) from baseline', \"Change from baseline in St George's\", 'Respiratory Questionnaire (SGRQ-C)', 'Percentage of responders according to', 'SGRQ-C total score (defined as a 4', 'point or greater reduction from', '9']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Objectives', 'Enpoints', 'baseline)', 'Change from baseline in COPD', 'assessment test (CAT)', 'Percentage of responders according to', 'CAT (defined as a 22 unit improvement', 'in score from baseline)', 'Other', 'To compare UMEC/VI (62.5/25 mcg', 'Rate of mild, moderate or', 'severe', 'once daily), UMEC (62.5 mcg once', 'exacerbations', 'daily) with salmeterol (50 mcg twice', 'daily) on other COPD efficacy measures', 'Time to first mild, moderate or severe', 'exacerbation', 'Rate of moderate or severe', 'exacerbation', 'Time to moderate or severe', 'exacerbation', 'Time to severe exacerbations', 'Time to clinically important', 'deterioration (CID) composite endpoint', 'Time to clinically important', 'deterioration composite endpoint', 'excluding FEV1', 'Rescue albuterol/salbutamol use,', '(percentage of rescue-free days and', 'mean number of Inhalations/day)', 'captured by the electronic diary', '(eDiary) over 24 weeks', 'Inspiratory capacity (IC)', 'Full Vital capacity (FVC)', 'Change from baseline in trough FEV1', 'Change from baseline in global', 'impression of disease severity', '10']\n\n###\n\n", "completion": "END"}